Biomarkers for cognitive impairment and dementia in elderly people
暂无分享,去创建一个
T. Montine | J. Kaye | J. Quinn | J. Breitner | K. Montine | J. Sonnen | Thomas J Montine | Jeffrey A Kaye | Joseph F Quinn | Joshua A Sonnen | Kathleen S Montine | John CS Breitner
[1] R. Katzman.,et al. The Prevalence and Malignancy of Alzheimer Disease A Major Killer , 2008, Alzheimer's & Dementia.
[2] W. M. van der Flier,et al. Longitudinal changes of CSF biomarkers in memory clinic patients , 2007, Neurology.
[3] T. Montine,et al. Cerebrospinal Fluid Aβ42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls , 2001 .
[4] S. Black,et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards , 2006, Stroke.
[5] K. Blennow. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[6] H. Wiśniewski,et al. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. , 1994, Neurobiology of aging.
[7] Ge Li,et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.
[8] S. Haneuse,et al. Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.
[9] T. Montine,et al. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. , 2001, Archives of pathology & laboratory medicine.
[10] Johannes Kornhuber,et al. Blood‐based neurochemical diagnosis of vascular dementia: a pilot study , 2007, Journal of neurochemistry.
[11] D. Schaid,et al. Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees , 2001 .
[12] G. Annoni,et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.
[13] J. Orgogozo,et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia , 2004, Journal of the Neurological Sciences.
[14] David M Holtzman,et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.
[15] Henrik Zetterberg,et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF , 2005, Experimental Neurology.
[16] P. Calabresi,et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies , 2008, Biological Psychiatry.
[17] C. Patterson,et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging , 2007, Neurobiology of Aging.
[18] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[19] Hae Ri Na,et al. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease , 2008, Neuroscience Letters.
[20] P. Aisen,et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. , 2000, Neurology.
[21] R. Mayeux,et al. Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .
[22] K. Blennow,et al. Neurofilament protein in cerebrospinal fluid: A marker of white matter changes , 2001, Journal of neuroscience research.
[23] R. Petersen,et al. Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .
[24] D. Kiel,et al. Inflammatory markers and the risk of Alzheimer disease , 2007, Neurology.
[25] Peter P. Zandi,et al. Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .
[26] James P. Malone,et al. Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S , 2005, Molecular & Cellular Proteomics.
[27] T. Tokuda,et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .
[28] P. Scheltens,et al. CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls , 2007, Dementia and Geriatric Cognitive Disorders.
[29] K. Blennow,et al. Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.
[30] D. Perani,et al. FLUCTUATIONS OF CSF AMYLOID-β LEVELS: IMPLICATIONS FOR A DIAGNOSTIC AND THERAPEUTIC BIOMARKER , 2007, Neurology.
[31] H. Engler,et al. In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[32] Henrik Zetterberg,et al. Alzheimer's disease , 2006, The Lancet.
[33] Gunhild Waldemar,et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.
[34] H. Arai,et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. , 2004, Archives of neurology.
[35] K. Blennow,et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease , 2009, Neurobiology of Aging.
[36] W. Jagust,et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. , 2007, Brain : a journal of neurology.
[37] Norman Relkin,et al. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.
[38] J. Adair,et al. Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease , 2004, Stroke.
[39] Paul Edison,et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.
[40] D J Brooks,et al. DLB and PDD boundary issues , 2007, Neurology.
[41] K. Blennow,et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.
[42] B. Miller,et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.
[43] Kaj Blennow,et al. Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .
[44] K. Blennow,et al. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia , 1992, Acta neurologica Scandinavica.
[45] K. Blennow,et al. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment , 1999, Neuroscience Letters.
[46] K. Blennow,et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI , 2007, Neurology.
[47] Ian G. McKeith,et al. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.
[48] B. Hyman,et al. Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .
[49] B. Hyman,et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.
[50] J. Morrow,et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.
[51] C. Rowe,et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.
[52] K. Blennow,et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.
[53] Chris Zarow,et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology , 2006, Annals of neurology.
[54] R. Petersen. The current status of mild cognitive impairment—what do we tell our patients? , 2007, Nature Clinical Practice Neurology.
[55] Christine Van Broeckhoven,et al. No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease , 2007 .
[56] K. Blennow,et al. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.
[57] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[58] H. Wiśniewski,et al. α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease , 1994, Neurobiology of Aging.
[59] K. Blennow,et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy , 2000, Journal of neurology, neurosurgery, and psychiatry.
[60] J. Hardy,et al. The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.
[61] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[62] G. Waldemar,et al. A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia , 2007, Dementia and Geriatric Cognitive Disorders.
[63] T. Montine,et al. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.
[64] F. Jessen,et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study , 2008, Neurobiology of Aging.
[65] K. Blennow,et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.
[66] P. Lewczuk,et al. CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006, Brain : a journal of neurology.
[67] F. Schmitt,et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.
[68] T. Montine,et al. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.
[69] J. Trojanowski,et al. Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.
[70] Wiesje M. van der Flier,et al. CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.
[71] S. Hirai,et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.
[72] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[73] K. Blennow,et al. A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.
[74] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[75] K. Blennow,et al. Prediction of Alzheimer’s Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides , 2008, Neurodegenerative Diseases.
[76] J. Growdon,et al. Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease , 2007, Neurodegenerative Diseases.
[77] J. Sidtis,et al. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[78] J. Schneider,et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology , 2004, Neurology.
[79] K. Blennow,et al. Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.
[80] Holly Soares,et al. Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.
[81] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[82] Hilkka Soininen,et al. CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.
[83] W. Markesbery,et al. Cerebrovascular Pathology and Dementia in Autopsied Honolulu‐Asia Aging Study Participants , 2002, Annals of the New York Academy of Sciences.
[84] Katharina Buerger,et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.
[85] R. Freedland,et al. Increased amyloid β protein levels in children and adolescents with Down syndrome , 2007, Journal of the Neurological Sciences.
[86] A. Hofman,et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.
[87] M. Sjögren,et al. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia , 2001, Mechanisms of Ageing and Development.
[88] John Hardy,et al. Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.
[89] Charles DeCarli,et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.
[90] M. Michalopoulou,et al. Serum Levels of Soluble Intercellular Adhesion Molecule-1 and Soluble Endothelial Leukocyte Adhesion Molecule-1 in Alzheimer’s Disease , 2004, Journal of geriatric psychiatry and neurology.
[91] J. Becker,et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.
[92] T. Montine,et al. Quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. , 2001, Advances in experimental medicine and biology.
[93] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[94] O. Selnes,et al. Vascular cognitive impairment , 2006, Nature Clinical Practice Neurology.
[95] R. Maccioni,et al. Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects , 2006, Neurobiology of Aging.
[96] Albert Hofman,et al. Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.
[97] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[98] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[99] T. Beach,et al. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.
[100] J. Trojanowski,et al. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease , 2007, Acta Neuropathologica.
[101] Jing Zhang,et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.
[102] B L Miller,et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease , 2007, Neurology.
[103] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[104] S. Papageorgiou,et al. Diagnostic Value of CSF Biomarker Profile in Frontotemporal Lobar Degeneration , 2008, Alzheimer disease and associated disorders.
[105] Katharina Buerger,et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.
[106] J. Trojanowski,et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.
[107] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[108] J. Trojanowski,et al. Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[109] B. Reisberg,et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.
[110] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[111] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[112] H. Arai,et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.
[113] G. Schellenberg,et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. , 2006, Journal of Alzheimer's disease : JAD.
[114] A. Verma,et al. Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy , 2008 .
[115] A. Fagan,et al. Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation , 2007, Annals of neurology.
[116] G. Davı̀,et al. Determinants of platelet activation in Alzheimer's disease , 2007, Neurobiology of Aging.
[117] Keith A. Johnson,et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.
[118] G. Bernardi,et al. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis , 2005, Journal of the Neurological Sciences.
[119] C. Brayne,et al. Neuropathological Findings in the Very Old: Results from the First 101 Brains of a Population‐based Longitudinal Study of Dementing Disorders , 2000, Annals of the New York Academy of Sciences.
[120] T. Montine,et al. Increased CSF F2-isoprostane concentration in probable AD , 1999, Neurology.
[121] T. Montine,et al. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. , 2001, The American journal of pathology.
[122] T. Tokuda,et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.
[123] S. Hirai,et al. α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .
[124] B. L. Miller,et al. 11 CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007 .
[125] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[126] Jean-Christophe Rochet,et al. Novel therapeutic strategies for the treatment of protein-misfolding diseases , 2007, Expert Reviews in Molecular Medicine.
[127] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[128] T. Montine,et al. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. , 2005, Antioxidants & redox signaling.
[129] Nobuyuki Okamura,et al. CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study , 2000, Experimental Neurology.
[130] Yvette I. Sheline,et al. Potential antecedent marker of Alzheimer disease , 2006 .
[131] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[132] I. Sokal,et al. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.
[133] J. Schneider,et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.
[134] K. Blennow,et al. Increased levels of CSF phosphorylated tau in apolipoprotein E ɛ4 carriers with mild cognitive impairment , 2005, Neuroscience Letters.
[135] J. Kaye,et al. Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.
[136] Henrik Zetterberg,et al. Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.
[137] Yan Liu,et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.
[138] Jennifer Farmer,et al. Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.
[139] L. Fratiglioni,et al. Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.
[140] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[141] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.